How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,765 results for

Urinary Incontinence due to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Urinary incontinence and pelvic organ prolapse in women: management

. The review should cover: routine assessment of continence assessment of skin integrity changes to symptoms, comorbidities, lifestyle, mobility, medication, BMI, and social and environmental factors the suitability of alternative treatment options the efficacy of the absorbent containment product the woman is currently using and the quantities used. [2019] [2019] 1.4.18 Reviews for women who are using absorbent containment products for long- term management of urinary incontinence should be carried out (...) Urinary incontinence and pelvic organ prolapse in women: management Urinary incontinence and pelvic organ Urinary incontinence and pelvic organ prolapse in women: management prolapse in women: management NICE guideline Published: 2 April 2019 nice.org.uk/guidance/ng123 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. The management of urinary incontinence in women

The management of urinary incontinence in women Urinary incontinence in women The management of urinary incontinence in women bpac nz guidelines www.bpac.org.nz/guidelines May 20162 THE MANAGEMENT OF URINARY INCONTINENCE IN WOMEN www.bpac.org.nz/guidelines/2 This is a bpac nz contextualisation of NICE Clinical Guideline 171 © NICE 2013 2 Contents Introduction 4 Patient-centred care 5 Key priorities for implementation 6 Cultural considerations 6 History-taking and physical examination 6 (...) Assessment of pelvic floor muscles 6 Bladder diaries 6 Absorbent products, urinals and toileting aids 6 Indwelling urethral catheters 6 General principles when using overactive bladder (OAB) medicines 7 Choosing OAB medicines 7 Surgical approaches for stress urinary incontinence (SUI) 7 The multidisciplinary team (MDT) 7 Maintaining and measuring surgical expertise and standards for practice 7 1. Recommendations 8 1.1 Assessment and investigation 8 1.2 Lifestyle interventions 11 1.3 Physical therapies 11

2019 Best Practice Advocacy Centre New Zealand

3. Urinary Incontinence

incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study. Urology, 2009. 73: 1203. 93. Coyne, K.S., et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn, 2013. 32: 230. 94. Diokno, A.C., et al. Medical correlates of urinary incontinence in the elderly. Urology, 1990. 36: 129. 95. Alling Moller, L., et al. Risk factors for lower (...) . Cochrane Database Syst Rev, 2013: CD001202. 183. Lim, R., et al. Efficacy of electromagnetic therapy for urinary incontinence: A systematic review. Neurourol Urodyn, 2015. 34: 713. 184. Wallace, P.A., et al. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol, 2007. 197: 96 e1. 185. Finazzi-Agro, E., et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo

2019 European Association of Urology

4. Urinary Incontinence due to Medications

Urinary Incontinence due to Medications Urinary Incontinence due to Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Urinary Incontinence due to Medications Urinary Incontinence due to Medications Aka: Urinary Incontinence due to Medications , Medication Causes of Urinary Incontinence , Drug-Induced Urinary Incontinence II. Causes: Antihypertensive s High s with secondary and contractions s Relaxes Alpha-adrenergic antagonists Decreases l sphincter tone However, alpha blockers reduce in s including s Muscle relaxants Sympathetic blockers III. Causes: Analgesic s relaxation, and sedation result in s contraction

2018 FP Notebook

5. Transurethral Injection of Botulinum Toxin into the Bladder Wall for Urinary Incontinence due to Neurogenic Detrusor Overactivity

Transurethral Injection of Botulinum Toxin into the Bladder Wall for Urinary Incontinence due to Neurogenic Detrusor Overactivity 1/7 Public Summary Document Application No. 1221 – Intravesical injection of BOTOX ® (botulinum toxin) for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) Sponsor/Applicant/s: Allergan Australia Pty Ltd Date of MSAC consideration: 5 April 2013 1. Purpose of application In August 2011, an application to the Medical Services Advisory (...) by anticholinergic agents. This does not include idiopathic overactive bladder.” 4. Proposal for public funding Applicant’s proposed MBS item descriptor to the November 2012 MSAC meeting GROUP T11 – BOTULINUM TOXIN INJECTIONS (Division 2.42A of the General Medical Services Table (GMST) Regulations BOTULINUM TOXIN (Botox), transurethral injection of, for the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who have failed or are intolerant to anti- cholinergic therapy

2013 Medical Services Advisory Committee

6. Transurethral Injection of Botulinum Toxin (Botox) into the Bladder Wall for Urinary Incontinence due to Idiopathic Overactive Bladder

Final DAP for Application 1272 (February 2013) and the fee for intravesical injection of botulinum toxin type A for urinary incontinence due to neurogenic detrusor overactivity (57th MSAC Meeting minutes, Application 1221). The following MBS item was proposed: Applicant proposed wording and fee for the requested MBS item Group T11 – Botulinum toxin Division 2.42A of the General Medical Services Table MBS item no: TBA (within Group T11) BOTULINUM TOXIN (Botox), intravesical injection (...) of, for the treatment of urinary incontinence due to idiopathic overactive bladder, including cystoscopy and all injections in one day, but not provided on the same occasion as a service described in item 11900, in patients aged 18 years or older who have failed or are intolerant to anti-cholinergic medications, and who are willing and able to self-catheterise. (Anaes.) (See para T11.1 of explanatory notes to this Category) MBS Fee: $229.85 Benefit: 75% = $172.40 As noted in the final DAP, the MBS item would

2013 Medical Services Advisory Committee

7. Urinary Incontinence

incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study. Urology, 2009. 73: 1203. 93. Coyne, K.S., et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn, 2013. 32: 230. 94. Diokno, A.C., et al. Medical correlates of urinary incontinence in the elderly. Urology, 1990. 36: 129. 95. Alling Moller, L., et al. Risk factors for lower (...) . Cochrane Database Syst Rev, 2013: CD001202. 183. Lim, R., et al. Efficacy of electromagnetic therapy for urinary incontinence: A systematic review. Neurourol Urodyn, 2015. 34: 713. 184. Wallace, P.A., et al. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol, 2007. 197: 96 e1. 185. Finazzi-Agro, E., et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo

2018 European Association of Urology

8. Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder

Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder Medical Services Advisory (...) Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1272. 2013 Authors' conclusions MSAC supported

2013 Health Technology Assessment (HTA) Database.

9. Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline

, pressure-flow study, and PVR assessment. Urinary incontinence may also occur due to a urethral diverticulum, a urinary fistula, or an ectopic ureter. These entities are often suspected on the basis of history and examination, but generally require cystoscopy and other urinary tract imaging for confirmation. Certain coexistent conditions may influence surgical technique, impact the outcomes of treatment, and influence the nuances of patient counseling. For example, a patient with MUI who has a large PVR (...) Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline 1 Purpose Stress urinary incontinence (SUI) is a common problem experienced by many women. SUI can have a significant negative impact on the quality of life (QOL) of not only those who suffer from the condition, but also potentially on those friends and family members whose lives and activities may also be limited. The surgical options for the treatment of SUI continue to evolve; as such, this guideline

2017 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction

10. Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline

, and PVR assessment. Urinary incontinence may also occur due to a urethral diverticulum, a urinary fistula, or an ectopic ureter. These entities are often suspected on the basis of history and examination, but generally require cystoscopy and other urinary tract imaging for confirmation. Certain coexistent conditions may influence surgical technique, impact the outcomes of treatment, and influence the nuances of patient counseling. For example, a patient with MUI who has a large PVR volume and detrusor (...) symptoms. If the patient expresses minimal subjective bother due to the SUI, then strong consideration should be given to conservative, non–surgical therapy. To this point, patients should be counseled on the risks, benefits, and alternatives to any intervention they may choose in addition to the concept that the primary goal of treatment is to improve QOL. Close Guideline Statement 8 In patients with stress urinary incontinence or stress-predominant mixed urinary incontinence who wish to undergo

2017 American Urological Association

11. Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity

Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity Medical Services Advisory Committee Record Status This is a bibliographic record of a published health (...) technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1221. 2012 Authors' conclusions After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost

2012 Health Technology Assessment (HTA) Database.

12. Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women

outcomes of all patients having extraurethral retropubic adjustable compression devices for stress urinary incontinence (see section 7.3). 1.3 All adverse events involving any medical devices used in this procedure should be reported to the Medicines and Healthcare products Regulatory Agency. 1.4 Further research into this procedure should include detailed safety outcomes, long-term results and patient-reported outcome measures. NICE may update the guidance on publication of further evidence. 2 2 (...) Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women Extr Extraurethr aurethral (non-circumferential) retropubic al (non-circumferential) retropubic adjustable compression de adjustable compression devices for stress urinary vices for stress urinary incontinence in women incontinence in women Interventional procedures guidance Published: 22 March 2017 nice.org.uk/guidance/ipg576 Y Y our responsibility our responsibility

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

13. Urinary incontinence in women: management

: The Government has announced a pause on the use of vaginally inserted mesh and tape to treat stress urinary incontinence and pelvic organ prolapse in England. This follows a recommendation by Baroness Cumberlege, who is chairing an independent review of surgical mesh procedures and has heard from women and families affected by them. For details, see the letter from NHS England and NHS Improvement to trust medical directors. We will work with NHS England to produce a shared decision making tool (...) Urinary incontinence in women: management Urinary incontinence in women: Urinary incontinence in women: management management Clinical guideline Published: 11 September 2013 nice.org.uk/guidance/cg171 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

14. Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

: Completed First Posted : July 29, 2016 Last Update Posted : January 29, 2019 Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: This study will evaluate the efficacy and safety of GSK1358820 in Japanese patients with neurogenic detrusor overactivity (NDO) with urinary incontinence, whose symptoms have not been adequately managed with medications for urinary incontinence due to NDO. This study consists of a screening (...) months prior to screening, determined by documented subject history. The presence of an involuntary detrusor contractions (IDC) must also be demonstrated during the urodynamic assessment during the screening period or Day 1 (prior to randomization). Subject has not been adequately managed with one or more medications (i.e., anticholinergics or beta-3 adrenergic receptor agonist) for treatment of urinary incontinence due to NDO . Not adequately managed is defined as: An inadequate response after

2016 Clinical Trials

15. Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2016 Clinical Trials

16. Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2016 Clinical Trials

17. Urinary incontinence in neurological disease: assessment and management

to young people with incontinence due to neurological disease. Diagnosis and management should be reviewed throughout the transition process, and there should be clarity about who is the lead clinician to ensure continuity of care. Urinary incontinence in neurological disease: assessment and management (CG148) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 47K Ke ey priorities for implementation y priorities (...) of the neurological disease bowel symptoms sexual function comorbidities use of prescription and other medication and therapies. 1.1.2 Assess the impact of the underlying neurological disease on factors that will Urinary incontinence in neurological disease: assessment and management (CG148) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 13 of 47affect how lower urinary tract dysfunction can be managed, such as: mobility hand

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

18. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial

sustainable UUI improvement, and higher BTX dosing had low clean intermittent catheterization rates, but with UTI risk. SNM revision/removal rates were low due to standardized lead placement with strict treatment response definitions.We compared a large group of US women with severe urgency urinary incontinence (UUI) who received sacral neuromodulation (InterStim) or onabotulinumtoxinA (Botox A) therapy during a 2-yr period. We found that both therapies had similar success in reducing UUI symptoms (...) Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial Urgency urinary incontinence (UUI) is a chronic condition for which sacral neuromodulation (SNM) (InterStim/Medtronic) and onabotulinumtoxinA (BTX) (BotoxA/Allergan) are utilized. These therapies have not been compared over extended time.To compare UUI episodes (UUIE) over 24 mo following SNM or BTX.Multicenter, open-label, randomized, extension trial (February

Full Text available with Trip Pro

2018 EvidenceUpdates

19. Male stress urinary incontinence, sling operation for, with or without synthetic mesh

Male stress urinary incontinence, sling operation for, with or without synthetic mesh 1 Public Summary Document Application No. 1369 – Insertion of a synthetic sling for the treatment of male stress urinary incontinence Applicant:American Medical Systems Australia Pty Ltd Date of MSAC consideration: MSAC 64 th Meeting, 30-31 July 2015 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, see at www.msac.gov.au 1. Purpose of application and links to other (...) applications An application requesting Medicare Benefits Schedule (MBS) listing of insertion, adjustment and removal of synthetic slings for the treatment of male stress urinary incontinence was received from American Medical Systems Australia Pty Ltd. The evidence for assessment of this application was submitted in March 2015. 2. MSAC’s advice to the Minister After considering the available evidence presented in relation to safety, clinical effectiveness and cost-effectiveness of synthetic slings

2015 Medical Services Advisory Committee

20. Single-incision short sling mesh insertion for stress urinary incontinence in women

Single-incision short sling mesh insertion for stress urinary incontinence in women Single-incision short sling mesh insertion for Single-incision short sling mesh insertion for stress urinary incontinence in women stress urinary incontinence in women Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When (...) . Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 11Ov Overview erview Evidence-based recommendations on single-incision short sling mesh insertion for stress urinary incontinence in women. This involves putting 2 short slings around the tube that carries urine from the bladder to support it. July 2018: July 2018: The Government has announced a pause on the use of vaginally inserted mesh and tape to treat stress urinary incontinence and pelvic

2016 National Institute for Health and Clinical Excellence - Interventional Procedures

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>